Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Adicionar filtros








Intervalo de ano
1.
Protein & Cell ; (12): 717-733, 2021.
Artigo em Inglês | WPRIM | ID: wpr-888715

RESUMO

The coronavirus disease 2019 (COVID-19) pandemic is caused by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is spread primary via respiratory droplets and infects the lungs. Currently widely used cell lines and animals are unable to accurately mimic human physiological conditions because of the abnormal status of cell lines (transformed or cancer cells) and species differences between animals and humans. Organoids are stem cell-derived self-organized three-dimensional culture in vitro and model the physiological conditions of natural organs. Here we showed that SARS-CoV-2 infected and extensively replicated in human embryonic stem cells (hESCs)-derived lung organoids, including airway and alveolar organoids which covered the complete infection and spread route for SARS-CoV-2 within lungs. The infected cells were ciliated, club, and alveolar type 2 (AT2) cells, which were sequentially located from the proximal to the distal airway and terminal alveoli, respectively. Additionally, RNA-seq revealed early cell response to virus infection including an unexpected downregulation of the metabolic processes, especially lipid metabolism, in addition to the well-known upregulation of immune response. Further, Remdesivir and a human neutralizing antibody potently inhibited SARS-CoV-2 replication in lung organoids. Therefore, human lung organoids can serve as a pathophysiological model to investigate the underlying mechanism of SARS-CoV-2 infection and to discover and test therapeutic drugs for COVID-19.


Assuntos
Humanos , Monofosfato de Adenosina/uso terapêutico , Alanina/uso terapêutico , Células Epiteliais Alveolares/virologia , Anticorpos Neutralizantes/uso terapêutico , COVID-19/virologia , Regulação para Baixo , Descoberta de Drogas , Células-Tronco Embrionárias Humanas/metabolismo , Imunidade , Metabolismo dos Lipídeos , Pulmão/virologia , RNA Viral/metabolismo , SARS-CoV-2/fisiologia , Replicação Viral/efeitos dos fármacos
2.
Chinese Journal of Biochemical Pharmaceutics ; (6): 123-125, 2017.
Artigo em Chinês | WPRIM | ID: wpr-514643

RESUMO

Objective To observe the clinical curative effect of Tanreqing injection of antibiotics in the treatment of pulmonary infection in the elderly.Methods 120 cases of elderly patients with pulmonary infection from June 2015 to June 2016 in our hospital were selected, randomly divided into observation group and control group,60 cases in each group, the observation group treated with Tanreqing injection and oxygen, anti-inflammatory, expectorant therapy,the control group treated only with oxygen, anti-inflammatory, expectorant therapy, the clinical symptoms and therapeutic effects were compared between the two groups.Results After seven days of treatment, PaO2 , SaO2 and pH of the observation group were higher than those of the control group (P<0.05), the levels of PaCO2, CRP, IL-6, IL-13, LTB4 and WBC were lower than those in the control group (P<0.05); After 14 days of treatment, CRP, IL-6, IL-13 and LTB4 in the observation group were lower than those in the control group (P<0.05); The total effective rate was 75.00%in the observation group and 58.33%in the control group after 14 days of treatment.There was significant difference between the two groups (P<0.05).Conclusion Tanreqing injection combined with western medicine antibiotic treatment of elderly patients with pulmonary infection was significant,can significantly improve the clinical symptoms of patients and improve clinical efficacy .

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA